ライフサイエンスコーパス: pulmonary TB

1 A subset of 25 pulmonary TB patients who had a positive skin reaction t

2 after intradermal injection of PPD among 364 pulmonary TB patients in Cambodia.

3 ncoded from detailed interviews of 76 and 64 pulmonary TB patients in the 2 Indian cities of Mumbai a

4 th latent TB infection (LTBI) and 107 active pulmonary TB (APTB) cases, and 24 recently BCG-vaccinate

5 icts/counties (each with at least 300 active pulmonary TB patients registered in 2009) within the pro

6 nted with untreated HIV infection and active pulmonary TB.

7 deep learning system (DLS) to detect active pulmonary TB on chest radiographs and compare its perfor

8 aerosol collection kit-for detecting active pulmonary TB using quantitative PCR (qPCR).

9 s I ranking HRCT criteria to diagnose active pulmonary TB were 95%, 40% and 1.4, respectively.

10 ssed in whole blood can differentiate active pulmonary TB (ATB) from other respiratory diseases (ORDs

11 tegies for evaluating outpatients for active pulmonary TB at the San Francisco Department of Public H

12 , 2 had TB lymphadenopathy, and 1 had active pulmonary TB.

13 Cases suspected of having active pulmonary TB whose smears are negative can benefit from

14 uberculosis test for the diagnosis of active pulmonary TB (PTB) with whole blood, plasma, and serum f

15 with symptoms and signs suggestive of active pulmonary TB that were systematically confirmed or ruled

16 We conducted a systematic review of active pulmonary TB treatment monitoring biomarkers.

17 5% CI: 86.2 to 100%) for diagnosis of active pulmonary TB when using sputum Xpert MTB/RIF as the refe

18 atients with class III ranking showed active pulmonary TB.

19 ern progression from latent (LTBI) to active pulmonary TB (PTB) remain poorly defined.

20 lt South African cohort (n = 72) with active pulmonary TB (on treatment for 1-4 mo) or pulmonary TB t

21 th symptoms and signs consistent with active pulmonary TB and complete clinical diagnosis were strati

22 were collected from 20 subjects with active pulmonary TB and from 20 healthy controls.

23 curacy of this assay in patients with active pulmonary TB and in control patients with or without lat

24 ensure that contacts of patients with active pulmonary TB are identified and appropriately screened.

25 rom study participants diagnosed with active pulmonary TB in South Africa and compared results to non

26 were identified for 349 patients with active pulmonary TB.

27 of sera from patients diagnosed with active pulmonary TB.

28 ne, provides variable efficacy against adult pulmonary TB, but why this protection varies is unclear.

29 children but is not effective against adult pulmonary TB.

30 Data were collected on all adult pulmonary TB patients registered at 25 public health cli

31 Xpert Ultra cartridge for diagnosis of adult pulmonary TB may have different consequences in differen

32 s, and restriction of this analysis to adult pulmonary TB.

33 We further find that after pulmonary TB infection, it still takes many days before

34 cine, Bacillus Calmette-Guerin (BCG) against pulmonary TB.

35 BCG can induce sterilizing immunity against pulmonary TB in nonhuman primates.

36 uced T cell responses and protection against pulmonary TB.

37 t implications in vaccine strategies against pulmonary TB and other intracellular infections in the l

38 sts could improve diagnosis of both EPTB and pulmonary TB (PTB) and timely initiation of anti-TB ther

39 sts could improve diagnosis of both EPTB and pulmonary TB (PTB), and timely initiation of anti-TB the

40 gene expression signature for both EPTB and pulmonary TB highlighting the translational potential of

41 South Africa, following adults with HIV and pulmonary TB prior to and up to 48 weeks after ART initi

42 after ART initiation in adults with HIV and pulmonary TB.

43 y influences susceptibility to meningeal and pulmonary TB by different immune mechanisms.

44 sted case-control study on air pollution and pulmonary TB, we observed positive associations with amb

45 re, we present a detailed comparison between pulmonary TB and SARC, including whole-blood gene expres

46 mental findings showed a causal link between pulmonary TB and lung tumorigenesis and established a ge

47 randomly selected U.S.-born and foreign-born pulmonary TB patients from 1993.

48 longitudinal cohorts of Indian and Brazilian pulmonary TB patients with or without DM.

49 patients on diagnostic delay experienced by pulmonary TB patients.

50 iciency virus-negative patients with chronic pulmonary TB.

51 dized patients (SPs) presenting with classic pulmonary TB symptoms were deployed in 3 provinces of Ch

52 proportion of younger patients with clinical pulmonary TB due to NTM and co-infection with HIV and th

53 extrapulmonary TB cases but not in clustered pulmonary TB cases.

54 years) had EPTB with or without concomitant pulmonary TB.

55 from adults with bacteriologically confirmed pulmonary TB were also comparable to those reported for

56 rolled adult patients with culture-confirmed pulmonary TB and their close contacts at 9 health depart

57 We used culture-confirmed pulmonary TB as the gold standard, and compared accuracy

58 3/51 (65%) and 33/51 (65%) culture-confirmed pulmonary TB cases, respectively; Xpert MTB/RIF detected

59 contacts of patients with culture-confirmed pulmonary TB in a multi-center Brazilian cohort.

60 ek) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil.

61 cipants: 95 with microbiologically confirmed pulmonary TB (Group 1), 200 household contacts of people

62 Contacts of microbiologically confirmed pulmonary TB cases were initially screened for longitudi

63 we enrolled 3109 microbiologically confirmed pulmonary TB patients and their 12 767 household contact

64 sed controls and microbiologically confirmed pulmonary TB patients.

65 nes in participants with previous or current pulmonary TB may have the potential for causing harmful

66 to discover a metabolic signature to detect pulmonary TB disease and monitor treatment response.

67 but less than 10% of those infected develop pulmonary TB.

68 All patients developed pulmonary TB, either alone or with extrapulmonary diseas

69 s associated with reduced risk of developing pulmonary TB but increased risk of rapid progression to

70 associated with increased risk of developing pulmonary TB.

71 41 subjects with newly-diagnosed pulmonary TB (cases) were compared to 82 healthy control

72 e of multi-detector HRCT chest in diagnosing pulmonary TB cases whose sputum smears are negative and

73 uding acetyl-CoA carboxylase 2 (ACC2) during pulmonary TB.

74 1 replication in alveolar macrophages during pulmonary TB.

75 sease-resistant and -susceptible mice during pulmonary TB.

76 ients presenting with a productive cough for pulmonary TB, Xpert blood offers no diagnostic advantage

77 form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration.

78 of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RI

79 om The Gambia and Uganda being evaluated for pulmonary TB.

80 m a genome-wide association study (GWAS) for pulmonary TB, we found that the response eQTL were more

81 approaches and experimental mouse models for pulmonary TB we characterized MDSCs as novel myeloid pop

82 We estimate risk ratios (RR) for pulmonary TB associated with BCG, IPT, and latent TB inf

83 mptom screening as the primary screening for pulmonary TB (PTB) disease.

84 f sputum (the primary specimen type used for pulmonary TB), careful design and reporting of the speci

85 We collected buccal swab samples from pulmonary TB patients at the commencement of TB treatmen

86 ure culture and clinical sputum samples from pulmonary TB patients.

87 antibody features that distinguish TBM from pulmonary TB.

88 All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary T

89 All had pulmonary TB, 5/14 (36%) had pulmonary and extrapulmonar

90 rolled hospitalized adults suspected to have pulmonary TB in Kampala, Uganda.

91 d 17-69 years; 62% male) diagnosed as having pulmonary TB diseases or non-TB diseases, but who could

92 iratory impairment in adults living with HIV/pulmonary TB.

93 terise, using RNA sequencing, 44 fresh human pulmonary TB lesion samples from 13 TB individuals (drug

94 3-Gal9 pathway plays a similar role in human pulmonary TB.

95 nd persistent in a subset of immunocompetent pulmonary TB patients and is characterized by antigen-sp

96 s such as navitoclax can potentially improve pulmonary TB treatments, reduce lung damage / fibrosis a

97 phagosome is a key reservoir of infection in pulmonary TB and multiple studies have shown that inorga

98 lung may affect presentation and outcome in pulmonary TB, and an understanding of the development of

99 of the systemic inflammatory perturbation in pulmonary TB and reveal qualitative changes in inflammat

100 rrow chimeras demonstrate that reductions in pulmonary TB immunopathology are dependent on hematopoie

101 0 mg/kg/d) rifampin-containing TB regimen in pulmonary TB.

102 Since the cellular immune response in pulmonary TB requires lymphocyte--macrophage interaction

103 ing might regulate monocyte MMP secretion in pulmonary TB during cell adhesion to the extracellular m

104 ity with both CCP and CAP frequently seen in pulmonary TB.

105 preventive therapy for persons with inactive pulmonary TB.

106 Between 2009 and 2012, we recruited incident pulmonary TB patients and their household contacts, whom

107 identified all adults (>15 yr) with incident pulmonary TB (index cases) diagnosed at 106 public healt

108 tween M. tuberculosis infection of the lung (pulmonary TB) and TBM.

109 inflammatory perturbation in treatment-naive pulmonary TB patients and uninfected individuals from In

110 From 1 June 2011 to 7 March 2012, 4,292 new pulmonary TB patients were enrolled across the 36 cluste

111 ed a prospective cohort of patients with new pulmonary TB receiving thrice-weekly treatment in India.

112 SA in the induced sputum samples from 56% of pulmonary TB patients.

113 en its accessibility and rapid assessment of pulmonary TB-related abnormalities.

114 ection, all animals remained asymptomatic of pulmonary TB.

115 ever, from May to September 1997, 3 cases of pulmonary TB were reported among medical waste treatment

116 examine the disease severity in a cohort of pulmonary TB (PTB) individuals with (Ss+) or without (Ss

117 Close contacts of pulmonary TB index cases exhibiting low Xpert MTB/RIF Ct

118 y was performed using records on contacts of pulmonary TB patients at the Public Health Service Amste

119 Contacts of pulmonary TB patients were enrolled in a prospective mul

120 Of 9,332 contacts of pulmonary TB patients, 4,774 were screened for latent TB

121 frequently are not used in the diagnosis of pulmonary TB cases, particularly TB cases with smear-neg

122 ements to sputum as samples for diagnosis of pulmonary TB in children.

123 ed on adult patients with first diagnosis of pulmonary TB starting treatment in public healthcare fac

124 is a reliable method for rapid diagnosis of pulmonary TB, irrespective of the AFB smear result.

125 abinomannan (LAM) would improve diagnosis of pulmonary TB.

126 s or DNA accumulate on the oral epithelia of pulmonary TB patients, and can be collected and detected

127 ociety where TB was prevalent, evaluation of pulmonary TB before prescription of PPI or H2RA is warra

128 The incidence of pulmonary TB was estimated in miners with and those with

129 personalized medicine for the management of pulmonary TB/cancer particularly for cases that are not

130 ssify the images as having manifestations of pulmonary TB or as healthy.

131 In this study, we used a rabbit model of pulmonary TB to evaluate the impact of adjunctive immune

132 n the highly susceptible guinea pig model of pulmonary TB, a model noteworthy for its close resemblan

133 otype of MCs was studied in 11 necropsies of pulmonary TB and 3 necropsies of non-TB infected lungs t

134 of follow-up, there were 55 observations of pulmonary TB in 52 persons, 26 observations of extrapulm

135 of age and BMI identified five phenotypes of pulmonary TB with significant differences at initial cli

136 populations (HIV/AIDS patients, survivors of pulmonary TB, cancer, chronic obstructive pulmonary dise

137 We enrolled adults with suspicion of pulmonary TB from health facilities in southwestern Ugan

138 Outpatient adults with signs/symptoms of pulmonary TB were prospectively enrolled.

139 patient adults with signs and/or symptoms of pulmonary TB were prospectively enrolled.

140 mmune modulation to improve the treatment of pulmonary TB and reduce the risk of chronic respiratory

141 thesized that aerosol IFN-gamma treatment of pulmonary TB would increase expression of genes importan

142 es for host-directed adjunctive treatment of pulmonary TB.

143 ve pulmonary TB (on treatment for 1-4 mo) or pulmonary TB treated at least 12 months before study ent

144 deep learning framework to detect pediatric pulmonary TB by identifying TB-compatible CXRs with cons

145 ry TB compared to bacteriologically positive pulmonary TB (RR, 1.10 [95% CI: 1.06-1.14]).

146 were obtained for cases of culture-positive pulmonary TB (PTB; 91.3%) and extrapulmonary TB (EPTB; 9

147 pproximately 54 (74%) of 72 culture-positive pulmonary TB cases over a 1-year period while requiring

148 lates from patients who had culture-positive pulmonary TB in Iqaluit, Nunavut, between 2009 and 2015

149 Comparison of serum from culture-positive pulmonary TB patients and TB suspects systematically rul

150 ve inpatients, 46 (39%) had culture-positive pulmonary TB.

151 Consecutive adult smear-positive pulmonary TB patients presenting to an urban hospital in

152 um samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 inter

153 ial in which individuals with smear-positive pulmonary TB with isoniazid resistance mediated by an in

154 n 4 of 16 subjects (25%) with smear-positive pulmonary TB.

155 We evaluated smear-positive, pulmonary TB notifications of foreign-born individuals,

156 was conducted using sputa from 426 possible pulmonary TB subjects from two small Mexican cities bord

157 sputum induction effectiveness for presumed pulmonary TB.

158 Hospital, Thailand, 204 adults with presumed pulmonary TB and negative Xpert MTB/RIF Ultra results or

159 NMR (bNMR) in Nigerian adults with presumed pulmonary TB, including individuals with and without HIV

160 rts, restricted to children with presumptive pulmonary TB < 10 years, and including children in high-

161 ly variable and the vaccine does not prevent pulmonary TB, the most common form of the illness.

162 re effective vaccination strategy to prevent pulmonary TB, the most common and contagious form of the

163 ine to participants with current or previous pulmonary TB induced a robust immune response and is not

164 ens, in individuals with current or previous pulmonary TB.

165 the overwhelming majority of culture-proven pulmonary TB cases are diagnosed from the first or secon

166 monary TB compared with patients with purely pulmonary TB (p = 0.01) and was amplified 2.6-fold at di

167 om PPD-anergic as compared with PPD-reactive pulmonary TB patients.

168 Patients with isoniazid-resistant pulmonary TB were recruited and followed up for 24 month

169 hirty-nine patients with isoniazid-resistant pulmonary TB were recruited.

170 ohort analysis of adults with drug-sensitive pulmonary TB at 5 sites from 2015-2019.

171 lder, had been diagnosed with drug-sensitive pulmonary TB in the past 4 weeks, smoked daily, were wil

172 bacteriologically confirmed, drug-sensitive pulmonary TB who were eligible to start first-line anti-

173 organs/tissues in the progression of severe pulmonary TB.

174 s safe for the treatment of drug-susceptible pulmonary TB (DS-PTB) compared with the standard 6-month

175 ding all adults treated for drug-susceptible pulmonary TB at 18 health facilities across Uganda over

176 ngitudinal cohort study, 40 drug-susceptible pulmonary TB patients (aged 18-69 years; 60% male) were

177 nsidering participants with drug-susceptible pulmonary TB who initiated standard TB therapy.

178 nts with culture-confirmed, drug-susceptible pulmonary TB who started first-line anti-TB therapy and

179 tment for culture-confirmed drug-susceptible pulmonary TB.

180 dentified patients with rifampin-susceptible pulmonary TB were enrolled in a first-in-human study(4)

181 ncluded culture-confirmed, drug-susceptible, pulmonary TB participants receiving standard treatment i

182 c sputum evaluation with Xpert for suspected pulmonary TB, in each of 3 emblematic settings: an HIV c

183 om 201 South African children with suspected pulmonary TB.

184 We identified that pulmonary TB patients have reduced expression of Tim3 on

185 It is well understood that pulmonary TB is due to Mtb growth in the lung but quanti

186 conditional logistic regression models, the pulmonary TB odds ratios (95% confidence intervals) for

187 , that are promising susceptibility genes to pulmonary TB.

188 ophozoites and cysts to Balb/c mice leads to pulmonary TB.

189 to meningeal TB (OR, 3.02; P < .001) than to pulmonary TB (OR, 1.55; P = .22).

190 treated for drug-susceptible, uncomplicated pulmonary TB.

191 2) years, with 63 (54%) females and 94% with pulmonary TB.

192 nal study that recruited 50 adolescents with pulmonary TB and 50 controls exposed to TB in Cape Town,

193 erivative (PPD), in HIV-negative adults with pulmonary TB (n = 10) versus TBM (n = 60).

194 V)-infected and 416 HIV-negative adults with pulmonary TB at the time of initiating chemotherapy and

195 rculosis Severity study compared adults with pulmonary TB in Chennai, India, who were classified as h

196 wed 14 044 household contacts of adults with pulmonary TB.

197 A, in adults who have had close contact with pulmonary TB patients living in TB-endemic areas, is a s

198 hese individuals to residents diagnosed with pulmonary TB at local health facilities and a representa

199 uated adult patients who were diagnosed with pulmonary TB from 2009 to 2014 in King County, Washingto

200 nt characteristics than those diagnosed with pulmonary TB in health facilities.

201 ed and forty six persons were diagnosed with pulmonary TB in the time period analyzed.

202 count in contacts of patients diagnosed with pulmonary TB.

203 fying the infection risk of individuals with pulmonary TB (PTB) to their household contacts.

204 tissue microarrays from 44 individuals with pulmonary TB and 25 control subjects.

205 by monocytes, compared with individuals with pulmonary TB, despite having lower IgG titres and Fcgamm

206 Patients with pulmonary TB (n = 49) and healthy volunteers with presum

207 -CCP and anti-CAP in sera from patients with pulmonary TB (n = 49), RA patients (n = 36), and control

208 ccal swabs were collected from patients with pulmonary TB (n = 7), TB-exposed persons (n = 7), and co

209 ere evaluated in 358 Cambodian patients with pulmonary TB and 106 tuberculin-positive control subject

210 We studied 21 patients with pulmonary TB and 7 healthy subjects.

211 Here we study 681 patients with pulmonary TB and show that M. tuberculosis isolates from

212 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center

213 ith pulmonary TB.METHODSThirty patients with pulmonary TB were enrolled within 7 days of initiating a

214 veolar lavage (BAL) cells from patients with pulmonary TB would have increased spontaneous release of

215 Moreover, in patients with pulmonary TB, lung damage correlated with increased seru

216 oad-spectrum MMP inhibitor, in patients with pulmonary TB.METHODSThirty patients with pulmonary TB we

217 up 1), 200 household contacts of people with pulmonary TB (Group 2), and 50 with a recent history of

218 e of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for childre

219 illion genetic variants in 5,530 people with pulmonary TB and in 5,607 healthy controls.

220 Plasma from Ethiopian persons with pulmonary TB at diagnosis (n = 82) was compared to house

221 agnostic features, we enrolled subjects with pulmonary TB (N = 149) and controls with other respirato

222 A total of 4,370 subjects with pulmonary TB were enrolled in the study.

223 .11) were more likely to die than those with pulmonary TB.

224 Adults aged >=65 years with pulmonary TB had less-advanced disease but a higher risk